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BACKGROUND. MicroRNAs are noncoding small RNA that negatively regulate target gene
expression by binding to the 30-UTR of mRNA. Previous studies have shown that several
microRNAs play a pivotal role in prostate cancer by acting as oncogenes or tumor suppressors.
This study was aimed at identifying microRNAs that contribute to the progression to
castration resistant prostate cancer.
METHODS. MicroRNAs expression profiles of a xenograft model and cell lines were
examined by microarray analysis and real-time PCR. Functional analysis of miR-582-5p in
cellular proliferation was examined by cell counting. Furthermore, in order to investigate a
candidate target of miR-582-5p, microarray analysis and analysis in silico were utilized.
RESULTS. MiR-582-5p was identified to be up-regulated at the castration resistant stage of a
xenograft model, KUCaP2 and in castration resistant cell line, AILNCaP#1. Overexpression of
miR-582-5p increased the number and the percentage of S phase of LNCaP cells under
androgen deprived condition. Moreover, suppression of miR-582-5p decreased the number
and the percentage of S phase of AILNCaP#1 cells. Furthermore, we identified that miR-582-
5p down-regulates EFNB2 expression, which is down-regulated at the castration resistant
stage of a xenograft model, KUCaP2 and in castration resistant cell line, AILNCaP#1.
CONCLUSIONS. Our results suggest that up-regulation of miR-582-5p contributes to an
increase in the proliferation of prostate cancer cells under androgen deprived conditions.
Prostate # 2014 Wiley Periodicals, Inc.
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INTRODUCTION
MicroRNAs are non-coding small RNAs that func-
tion to regulate specific target mRNAs by binding to
complementary regions in the 30-UTR of their targets.
These molecules have been shown to be involved in
various biological processes, including proliferation,
apoptosis, differentiation, and development. A num-
ber of microRNAs have been reported to play a crucial
role in cancers by acting as oncogenes or tumor
suppressors [1–3]. In prostate cancer, alterations in the
expression profiles of microRNAs have been reported,
and some microRNAs have been demonstrated to play
a role in the progression of castration resistant prostate
cancer (CRPC) [4–6].
Most patients with prostate cancer progress to
CRPC after initial response to androgen deprivation
therapy. Although multiple hormonal therapies may
increase the time to progression, subsequent therapies
in men with CRPC, including the chemotherapy,
docetaxel have limited benefit [7].Therefore, identifica-
tion of the mechanisms involved in the progression to
CRPC is important for the development of novel
effective therapies.
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We have established a novel prostate cancer xeno-
graft model, KUCaP-2. KUCaP-2 tumors are derived
from locally recurrent CRPC specimens, harbor wild-
type AR and express PSA [8]. Using this model, we
previously reported gene expression profiles that corre-
spond to the transition to CRPC. In this model, tumors
regress soon after castration, but then reproducibly
restore their ability to proliferate after 1–2 months,
mimicking the clinical behavior of CRPC. In order to
investigate the role of microRNAs in the progression of
CRPC, we evaluated expression profiles by microarray
analysis of microRNAs derived from xenograft tumor
tissues obtained at the CRPC stage in comparison to
those at an androgen dependent stage. A total of 173
microRNAs were significantly over-expressed at the
CRPC stage in the xenograft model. With long term
culturing under androgen-deprived conditions, we
have also established a mutant counterpart of LNCaP
cells, AILNCaP#1 cells, which can proliferate under
androgen-deprived conditions. Using both transition
models, miR-582-5p was reproducibly up-regulated in
androgen independent states in comparison to andro-
gen dependent counterpart. Therefore, we analyzed
the contribution of miR-582-5p to the regulation of
prostate cancer cell proliferation under androgen-de-
prived conditions by over-expressing or reducing miR-
582-5p expression in LNCaP cells or AILNCaP#1 cells
respectively. Moreover, we found that miR-582-5p
directly targeted EFNB2 expression, which has been
shown to be down-regulated in CRPC (Oncomine
database). Taken together, our results suggest that miR-
582-5p may contribute to the development of CRPC
and may be a target for therapeutic development.
MATERIALANDMETHODS
Cell Cultures
The prostate cancer cell line, LNCaP, was obtained
from the American Type Culture Collection (Rockville,
MD). LNCaP cells were cultured routinely in RPMI
(Invitrogen, Carlsbad, CA) supplemented with 10%
FBS at 37°C in incubators with humidified air and 5%
carbon dioxide. The subline, AILNCaP#1, was estab-
lished using the same approach as described previously
[9], and was maintained in phenol red-free RPMI
supplemented with 10% CSFBS.
Cell Proliferation andCell CycleAnalysis
For cell counting, target cells were inoculated into
6 cm dishes at 25 10 cells/plate. After allowing 24 hr
incubation for cell adhesion, the number of cells was
determined as baseline on day 0 and thereafter on
days 2, 4, and 6. Cells were collected by trypsinization
and counted using a hemocytometer. In the cell
proliferation assay, 75 103 cells/100ml culture medi-
um were seeded on each well of 96-well plates and
cultured for 48 hr and 96 hr. Then, 10ml/well Cell
Proliferation Reagent Cell Counting Kit-8 (Dojindo
Laboratories, Kumamoto, Japan) was added and
incubated for 1 hr, and the absorbance of the formazan
product formed was detected at 450 and 650 nm with
a 96-well spectrophotometric plate reader. Cell cycle
was examined with fluorescence-activated cell sorting
(FACS) as described previously [9].
MicroarrayAnalysis and Real-time PCR
Small RNAs were extracted from cultured cells
using the mirVanaTM miRNA Isolation Kit (Applied
Biosystems, Foster City, CA) and cDNA was synthe-
sized from 500 ng–1mg small RNAs using the miScript
RT Kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocols. Total RNAwas isolated and
purified using the RNeasy Mini Kit (Qiagen, Valencia,
CA). Changes in miRNA expression were analyzed
using TORAY 3D-Gene Human miRNA microarray
ver.12.1. After quantile normalization, we evaluated
the results by t-test (P< 0.05) and fold changes (> 2.5-
fold) to select candidate microRNAs. Gene expression
changes in miR-582-5p transfectants were analyzed
using DNA microarray with GeneChip1 Human Gene
1.0 ST array and data mining software (GeneSpring
GX Version11.5.1). PCR was performed by miScript
SYBR Green PCR Kit (Qiagen, Valencia, CA) using the
Delta-Delta Ct method as previously described [10].




Pre-miR-582-5p precursor, anti-miR-582-5p miRNA
inhibitor, precursor negative control and inhibitor
negative control were purchased from Ambion Inc.
(Austin, TX). The cells were transfected with 30 nM of
precursors or inhibitors in serum free conditions using
siPORTTM NeoFXTM Transfection Agent according to the
manufacturer’s protocols. After transfection, the cells were
seeded into 96-well plates for cell proliferation assays.
Generation of Stable Clones ExpressingmiR-582-
5p orAnti-microRNAAgainstmiR-582-5p
The lentiviral vector expressing miR582-5p
(PMIRH582PA-1), the lentiviral vector for miRZip
anti-sense microRNA against miR-582-5p (MZIP582-
5p-PA-1) and control vectors were purchased from SBI
(Mountainview, CA). Each of these vectors and pack-
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aging plasmid mix (LV500A-1, SBI) were co-trans-
fected into 293T cells. After 48 hr, pseudoviral particles
in the supernatant were collected and concentrated by
centrifuge for 24 hr. After infecting target cells with the
pseudovirus containing supernatant, infected cells
expressing miR-582-5p were selected by FACS sorting.
miRZip infected cells were selected using puromycin
for 2 weeks.
PredictionofmicroRNATargets
To confirm the sequences of microRNAs, miRBase
(http://www.microna.org) was utilized. The target
genes of microRNAs were predicted by referring to
Targetscan (http://www.targetscan.org).
Luciferase ReporterAssay
We used Duo-Luciferase reporter vector pEZX-
MT01 (Genecopoeia, Rockville, MD) as a luciferase
vector. Custom 30UTR miRNA target clones for Hu-
man EFNB2 in pEZX-MT01 (EFNB2-01, EFNB2-02)
were purchased from Genecopoeia (Rockville, MD).
EFNB2-01 and EFNB2-02 contain 30UTR of EFNB2
position 2653–2682 and position 2967–2996, respectively.
LNCaP cells were cotransfected with Duo-Luciferase
reporter vector and Pre-miR-582-5p precursor or nega-
tive control. Cells were harvested 48 h after transfec-
tion and assayed with LucPairTM Duo-Luciferase
Assay Kit (Genecopoeia, Rockville, MD) according to
the manufacturer’s protocols.
Western Blotting
Western bloting was performed with each primary
antibody (AR, 1:400; PSA, 1:400; EFNB2, 1:250; b-actin,
1:5,000) as previously reported [9]. EFNB2 antibody
(HPA008999) was purchased from Sigma–Aldrich (St.
Louis, MO). AILNCaP#1 cells were collected 48 h after
anti-miR-582-5p miRNA inhibitor or negative control




Transition to Castration Resistant Stage in
KUCaP2XenograftModels
In order to investigate the role of microRNAs in the
progression of CRPC, we evaluated expression profiles
of microRNAs derived from the KUCaP2 xenograft
tumor tissues at the CRPC stage in comparison to
those at the androgen dependent (AD) stage (n¼ 4)
by microRNA microarray analysis. The data have
been deposited in GEO database (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc¼GSE55829). One
hundred seventy three microRNAs were significantly
over-expressed (P< 0.05) at the CRPC stage, six of
which (miR-374b, miR-582-5p, miR-101, miR-429, miR-
100, and miR-32) were up-regulated at the CRPC stage
by > 2.5-fold (Table I). Only three microRNAs (miR-
451, miR-486-5p, and miR-145) were significantly
down-regulated at the CRPC stage. To validate the
results, we evaluated expression of the six microRNAs
by real-time PCR (Fig. 1). The PCR analysis confirmed
that each of the six microRNAs was up-regulated at
the CRPC stage in comparison to AD stage.
miR-582-5p ExpressionwasUp-regulatedin
AILNCaP#1Cells in ComparisonWith LNCaP
Cells
In order to select miRNA candidates that might
participate in the transition to CRPC, we evaluated
expression levels of those microRNAs in the andro-
gen-dependent cell line, LNCaP and the androgen-
independent cell line, AILNCaP#1 utilizing real-time
PCR. AILNCaP#1 cells are able to proliferate under
androgen-deprived conditions and express the andro-
gen receptor but do not express PSA (Fig. 2A,B).
MiR-582-5p was the only miRNA over-expressed in
AILNCaP#1 cells among the six microRNAs studied
(Fig. 2C).
MiR-582-5pContributed to Prostate Cancer Cell
ProliferationUnderAndrogenDeprivedCondition
To investigate the role of miR-582-5p in prostate
cancer cell proliferation under androgen deprived
conditions, we performed cck-8 assays using transiently
over-expressing or under-expressing miR-582-5p. The
results revealed that transient transfection of





(t test AD vs. CR)
fold change
(log2) CR/AD
hsa-miR - 374b 0.0058 3.53
hsa-miR - 582-5p 0.0236 3.48
hsa-miR - 101 0.0228 2.97
hsa-miR - 429 0.0009 2.55
hsa-miR - 100 0.0096 2.51
hsa-miR - 32 0.0123 2.5
AD, androgen-dependent growth stage.
CR, castration-resistant regrowth stage.
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number of LNCaP cells and transient transfection of
miR-582-5p inhibitor significantly suppressed the num-
ber of AILNCaP#1 cells under androgen deprived
conditions (data not shown). Stable transfection with
the miR-582-5p precursor (LNCaP miR-582-5p) was
verified to have expression levels 17-fold higher than
the empty vector (LNCaP EV) controls (Fig. 3A). Cck-8
and cell counting assays revealed that LNCaP miR-582-
5p cells increased in number under androgen deprived
conditions, although the LNCaP EV cells did not
increase in number under the same conditions (Figs. 3B
and C). Furthermore, the cell cycle distributions of
LNCaP miR-582-5p cells under androgen deprived
conditions demonstrated an increase in the percentage
of S phase cells, revealing that miR-582-5p promoted
cell proliferation of LNCaP cells under androgen
deprived conditions (Fig. 3D). Conversely, stable trans-
fection with the miR-582-5p inhibitor (miR-ZIP) in
AILNCaP#1 cells was confirmed to have expression
levels that were 0.17-fold of miR-582-5p compared to
the scramble vector (scramble) (Fig. 4A). The Cck-8
assay, cell counting assay and cell cycle analysis
showed that reduction of miR-582-5p expression sup-
Fig. 1. Validation of microRNA expression profiles of KUCaP2
xenograft models. Real- time PCR revealed that six microRNAs
(miR-374b, miR-582-5p, miR-101, miR-429, miR-100, andmiR-32)
were up-regulated in CRPC stage. FC means fold change (log2).
Eachbarrepresents themean SDof fourxenograft tissues.
Fig. 2. AILNCaP#1cells can proliferate under androgen deprived conditions. miR-582-5p expressionwas up-regulated in AILNCaP#1
cells in comparisonwith LNCaPcells. (A) Forcell counts, cellswere inoculatedinto 6 cmdishes at 25104 cells/plate inphenolred-freeRPMI
þ 10% CSFBS. After 24hr incubation for cell adhesion, the number of cells was counted as baseline on day 0 and thereafter on days 2, 4, 6,
and 8.Cellswere collectedby trypsinization and countedusing a hemocytometer. (B)Westernblotting analysis ofAR and PSAexpression in
AILNCaP#1cells.LNCaP cellswereused as a positive control.b-actinwas used as a loading control. After cultured in androgen deprivation
for 96hr,LNCaPcellswere treatedwith the indicateddose ofR1881for 24hr. AILNCaP#1cellswere culturedinphenolred-freeRPMIþ10%
CSFBS for 48hr and culturedwith the indicated dose of R1881for 24hr. (C) MicroRNA expression levels in the castration-resistant cell line
AILNCaP#1assessedbyreal-timePCR.Eachbarrepresents themean SDof threeindependentexperiments.
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pressed cell proliferation of AILNCaP#1 cells under
androgen deprived conditions (Figs. 4B,C and D).
These results demonstrate that, at least in LNCaP cell
model, miR-582-5p may contribute to the transition to
androgen independent cell proliferation.
MiR-582-5p Reduced the Expression Levelof
EFNB2
To investigate targets of miR-582-5p that which
might participate in the transition to CRPC, we
evaluated the gene expression profiles of LNCaP miR-
582-5p cells and LNCaP EV cells using DNA micro-
array analysis. The data have been deposited in GEO
database (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc¼GSE56669). We also compared the results
with gene expression profiles of the KUCaP2 CRPC
model previously described [8]. Thirteen genes were
down-regulated both in LNCaP miR-582-5p cells and
in KUCaP2 CRPC stage. Six of these 13 genes are
predicted to have target sites for miR-582-5p in their
30UTR by Targetscan (www.targetscan.org) (Table II).
According to a published database, expression levels
of EFNB2, a member of the ephrin family that has
been described as mediating developing, were signifi-
cantly decreased in CRPC compared to hormone-na€ıve
prostate cancer (Fig. 5A) [11]. There were no published
data regarding the other five genes, which revealed
Fig. 3. miR-582-5p contributes to prostate cancer cell proliferation under androgen-deprived conditions. (A) Real time PCR revealed
that stable transfectionwithmiR-582-5p precursor (LNCaPmiR-582-5p)was verified to be17-fold expression levels comparedwith empty
vector (EV) groups. (B) 75103 cells/100ul culturemedium seededon eachwell of 96-well plates and cultured for 48hr and 96hr under an-
drogendeprivedconditions.Then,10ul/wellCellproliferationReagentCellCountingKit-8 (DojindoLaboratories, Japan)was addedandincu-
bated for 1hr and the absorbance of the formazan product formed was detected at 450 and 650nm with a 96-well spectrophotometric
platereader. All experimentswererepeated two or three times.Data in apanelrevealed therepresentativeresult among threeindependent
experiments. (C) LNCaP miR-582-5p and LNCaP EV cells were inoculated into 6 cm dishes at 25104 cells/plate. After 24hr incubation
forcell adhesion, thenumberof cellswas countedasbaseline onday 0 and thereafterondays 2,4, and 6.Cellswere collectedby trypsinization
andcountedusing ahemocytometer.Data in apanelrevealed therepresentativeresultbetween two independentexperiments.Eachbarrep-
resents themean SD. (D)Cell cyclewas examinedwith fluorescence-activatedcell sorting.After 24hr inRPMIþ10%FBS for 24hr,LNCaP
mir-582-5p, and LNCaPEVcellswere inoculated inphenol-red freeRPMIþCSFBS for 48hr.Eachbar represents themean SD of three in-
dependentexperiments. * indicates P< 0.05.
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that those genes were down regulated in CRPC.
Targetscan revealed that EFNB2 contains two potential
target sites for miR-582-5p in its 30UTR (Fig. 5B).
Luciferase assay revealed that miR-582-5p decreased
the luciferase activity of reporter vectors containing
putative biniding site in the 30UTR of EFNB2 (Fig. 5C).
These results support Targetscan prediction indicating
the 30UTR of EFNB2 as a target of miR-582-5p. We
evaluated the expression level of EFNB2 at the mRNA
levels, in LNCaP miR-582-5p cells using real time PCR.
EFNB2 was significantly down regulated in LNCaP
miR-582-5p cells in comparison with LNCaP EV
cells under androgen-deprived conditions (Fig. 5D).
Western blotting analysis showed that miR-582-5p
decreased EFNB2 expression level in LNCaP cells, and
transient transfection of anti-miR-582-5p increased
EFNB2 expression level in AILNCaP#1 (Fig. 5E). These
findings denote that miR-582-5p negatively regulates
the expression of EFNB2.
DISCUSSION
A number of studies have shown that expression
levels of microRNAs are dysregulated in prostate
cancer and several microRNAs can act oncogenically
or as a tumor suppressor in prostate cancer cell
lines [6,12–15]. Several microRNAs have been reported
to induce prostate cancer cell proliferation under
Fig. 4. Reduction of miR-582-5p expression suppressed cell proliferation of AILNCaP#1cells. (A) Real time PCR revealed that stable
transfectionwithmiR-582-5pinhibitor (miR-ZIP)wasverifiedtobe0.17-foldexpressionlevelsofmiR-582-5pcomparedwithscramblevector
(scramble)groups. (B)75103 cells/100ulculturemediumseededoneachwellof96-wellplatesandculturedfor48hrand96hrunder andro-
gen-deprived condition.Then,10ul/well Cell proliferation ReagentCell Counting Kit-8was added and incubated for1hr, and the absorbance
of the formazan product formedwas detected at 450 and 650nmwith a 96-well spectrophotometric plate reader.Data in a panel revealed
the representative result among three independent experiments. (C) AILNCaP miR-ZIP and AILNCaP scramble cells were inoculated into
6 cmdishes at12104 cells/plate. After 24hr incubation for cell adhesion, thenumberof cellswas countedasbaseline onday 0 and thereafter
on days 2, 4, and 6.Cells were collected by trypsinization and counted using a hemocytometer.Data in a panel revealed the representative
resultbetween two independentexperiments.Eachbarrepresents themean SD. (D) Cell cyclewas examinedwith fluorescence-activated
cell sorting. After growth in phenol-red free RPMIþ10% CSFBS for 48hr, miR-ZIP and scramble cells were harvested by trypsinization.
Eachbarrepresents themean SDof threeindependentexperiments. * indicatesP< 0.05.
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androgen-deprived conditions [6,13–15]. These find-
ings suggest that microRNA may have an important
role in the development and regulation of CRPC.
In this study, we identified miR-582-5p to be up-
regulated both in the CRPC stage of the KUCaP2
model and in an androgen-independent cell line,
AILNCaP#1 in comparison with the controls. Further-
more, cell proliferation and cell cycle analyses revealed
that over expression of miR-582-5p induced LNCaP
cell proliferation in androgen-deprived conditions and
that reducing the expression of miR-582-5p suppressed
AILNCaP#1 cell proliferation. These results demon-
strated that at least in our independent models, miR-
582-5p might participate in the transition to CRPC. In
order to investigate miR-582-5p expression in other
androgen-independent prostate cancer cells, we also
evaluated its expression in PC3 and DU145 cells. The
expression levels observed in the PC3 cells was
comparable to that of LNCaP, but that of DU145 was
less than 1/5 of LNCaP (data not shown). Thus
AILNCaP#1 expressed extremely high level of miR-
582-5p in comparison to that of PC3 and DU145 cells.
Taken together, these data showed that over expres-
sion of miR-582-5p might contribute to transition of






EFNB2  2.697  2.004
RAB27A  1.787  2.615
MBOAT2  1.878  2.281
AFF3  2.225  1.219
SLC4A4  3.109  0.546
CAP2  1.629  0.744
Fold change (log2).
Fig. 5. MiR-582-5p reduced the expression levels of EFNB2 mRNA and protein. (A) A database published byTomlins et al. [11] showed
thatmRNA level of EFNB2 was significantly decreased in CRPC compared to that in hormone-na€ve prostate cancer (HNPC) P< 0.05. (B)
There are twomiR-582-5ppotentialbinding sites in the 3UTRof EFNB2. (C) EFNB2-01or EFNB2-02 luciferase constructs containing a po-
tential binding site of position 2675^2681or of position 2989^2995 representatively were transfected into LNCaPcellswithmiR-582-5p or
negative control. Luciferase activity was determined 24hr after transfection. Each bar represents the mean SD of three independent
experiments. (D) Real-time PCR analysis of EFNB2 expression in LNCaP EVand LNCaPmiR-582-5p.Eachbar represents themean SD of
three independent experiments. P< 0.05 (E) Western blotting analysis of EFNB2 expression. LNCaP EV is represented as EV, LNCaP miR-
582-5pasmiR,AILNCaP#1ctrlasCtrl, andAILNCaP#1anti-miR-582-5pas anti.
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to androgen-independent counterpart, but however,
cellular proliferation of androgen receptor negative
cells, such as PC3 and DU145, might fundamentally
depend upon other mechanisms rather than over-
expression of miR-582-5p. [16]
To our knowledge, this is the first report related to
the expression of miR-582-5p in prostate carcinoma. In
other cancer types, Uchino et al. recently demonstrated
that miR-582-5p and -3p reduced cell proliferation and
invasion of UM-UC-3 human bladder cancer cells
[17]. Apparently contrary findings by Ya-Ching Lu
et al. describe that miR-582-5p was significantly up-
regulated in oral cancers [18]. Amir et al. reported that
miR-125b acts as an oncogene, which regulates p14
(ARF)/Mdm2 in prostate cancer [19], however, Felic-
iano reported that miR-125b acts as a tumor suppres-
sor in breast tumorigenesis via the direct targeting of
ENPEP, CK2–a, CCNJ, and MEGF9 [20]. MiR-96 has
been reported to be up regulated in prostate cancer
and to enhance cellular proliferation of prostate cancer
cells [21]. Contrary, in T-cell lymphoma cell line and
non-small-cell lung cancer cell line, miR-96 decreases
proliferation, colony formation, and migration of
cancer cells [22]. All these reports suggested that
certain miRNAs (oncomiRs) could act as tumor sup-
pressors or as oncogenes according to the distinct
types of cancers being studied.
The androgen receptor (AR) plays a crucial role in
the development of prostate cancer and in the progres-
sion to CRPC [7,23,24]. Despite the importance of the
AR in regulating prostate cancer cells, western blotting
analysis showed that introduction of miR-582-5p to
LNCaP cells did not affect the expression levels of AR
and correspondingly, prostate specific antigen (PSA)
(data not shown). These findings suggest that AR may
not contribute to the transition to the castration-
resistant cell proliferation regulated by miR-582-5p in
LNCaP/AILNCaP#1 transition model.
Our study supported that EFNB2 is a direct target
of miR-582-5p at least in our LNCaP/AILNCaP#1
transition model. EFNB2 has a highly conserved miR-
582-5p binding site in its 30UTR, and luciferase activity
of EFNB2 30UTR reporter vector was reduced by the
transduced expression of miR-582-5p. Moreover, over-
expression of miR-582-5p reduced both mRNA and
protein expression levels of EFNB2 in LNCaP cells.
Furthermore, the reduction of miR-582-5p enhanced
EFNB2 protein level in AILNCaP#1 cells. The EFN
family are cell surface ligands of the EPH family
receptor kinases, and reverse signaling from receptors
to ligands is also known to be involved in cell-cell
interactions and compartmentalization [25]. Rutkow-
ski et al. reported that over expression of EphB4
confers a transformed phenotype in the case of MCF-
10A cells and an increased metastatic phenotype in the
case of 22Rv1 cancer cells and that both phenotypes
can be restrained by stimulation with EFNB2. The
authors concluded from their studies that EFNB2-
dependent signaling through EphB4 may act as a
tumor suppressor especially in cancer cells that express
EphB4 [26]. Moreover, Noren et al. reported that
EFNB2 reduced cell growth in MDA-MB-435 breast
cancer cells [27]. Therefore, the down-regulation of
EFNB2 by miR-582-5p may contribute to the accelera-
tion of prostate cancer cell proliferation. To confirm the
function of EFNB2 in cell proliferation under androgen
deprived conditions, we suppressed the expression of
EFNB2 in LNCaP cells using siRNA targeting EFNB2.
In our studies, the Cck-assays revealed that transient
knockdown of EFNB2 did not influence the prolifera-
tion of LNCaP cells under androgen-deprived condi-
tions (data not shown). Therefore, mere down-
regulation of EFNB2 was not sufficient for transition to
cell proliferation under androgen-deprived conditions
in LNCaP cells. In addition to EFNB2, other targets of
miR582-5p might participate in cell proliferation of
LNCaP cells in an androgen -deprived environment.
We also tried to overexpress EFNB2 in AILNCaP#1
cells. However, it was difficult to produce cells over-
expressing EFNB2. One additional complexity to our
studies is that LNCaP cells express a mutated AR,
which might influence the findings in that model
system.
In summary, our results suggest that up-regulation
of miR-582-5p contributes to an increase in the
proliferation of prostate cancer cells under androgen
deprived conditions. Further research is needed to
analyze the mechanisms of miR-582-5p mediated
development of CRPC, as well as ways in which these
findings can be utilized for therapeutic approaches.
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